Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018941 · ClinicalTrials.gov registry record · Phase 3
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00018941: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00018941 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018941, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of interleukin-2 in treating patients who have metastatic kidney cancer.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1991-04 |
| Est. Completion | 2003-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018941
The ClinicalTrials.gov registry entry for NCT00018941 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00018941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018941 about?
NCT00018941 is a clinical study titled "Interleukin-2 in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of interleukin-2 in treating patie...
What is the current status of trial NCT00018941?
This trial is currently completed. It is a Phase 3 study. The study started on 1991-04. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00018941?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00018941?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.